Get the Stockscreener App
11.28
6.21%
0.66
Pre-market:
11.28
Immunic Inc stock is traded at $11.28, with a volume of 272.77K.
It is up +6.21% in the last 24 hours and down -2.76% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
See More
Previous Close:
$10.62
Open:
$10.62
24h Volume:
272.77K
Relative Volume:
0.70
Market Cap:
$153.65M
Revenue:
-
Net Income/Loss:
$-97.17M
P/E Ratio:
-1.5111
EPS:
-7.465
Net Cash Flow:
$-85.97M
1W Performance:
+4.93%
1M Performance:
-2.76%
6M Performance:
+56.04%
1Y Performance:
+0.71%
1-Day Range:
$10.12
$11.29
1-Week Range:
$9.0501
$11.29
52-Week Range:
$5.062
$15.10
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
11.28 | 153.65M | 0 | -97.17M | -85.97M | -7.465 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-15-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
LifeSci Capital Initiates Immunic(IMUX.US) With Buy Rating, Announces Target Price $56 - Moomoo
[EFFECT] IMMUNIC, INC. SEC Filing - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Immunic to Participate in Investor and Medical Conferences in May - Sahm
Who's Buying or Selling Immunic Inc (HAM:10V) Stock Today? - GuruFocus
Immunic Inc (HAM:10V) Valuation - GuruFocus
Immunic Inc (HAM:10V) Dividend - GuruFocus
Immunic Inc (HAM:10V) Stock Price & 30 Year Financial Data - GuruFocus
Immunic Inc (HAM:10V) Competitors 2026 - GuruFocus
Immunic Inc (HAM:10V)Valuation Measures & Financial Statistics - GuruFocus
Immunic Inc Stock Baskets | HAM:10V - GuruFocus
Immunic Inc (HAM:10V) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Immunic Inc Stock Operating Data - GuruFocus
Immunic Inc (HAM:10V) Stock News, Headlines & Updates - GuruFocus
Immunic Inc (HAM:10V) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Immunic Inc (HAM:10V) Stock Earnings Transcripts - GuruFocus
Immunic (NASDAQ: IMUX) registers 45.8M shares after 1-for-10 reverse split - Stock Titan
Q3 2024 Immunic Inc Earnings Call Transcript - GuruFocus
Immunic (IMUX) price target increased by 920.41% to 54.64 - MSN
Immunic Inc (STU:10V) Stock Price & 30 Year Financial Data - GuruFocus
Immunic Inc (STU:10V) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Immunic Inc (STU:10V) Stock Earnings Transcripts - GuruFocus
H.C. Wainwright Maintains Immunic(IMUX.US) With Buy Rating, Cuts Target Price to $22 - Moomoo
IMUX Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus
H.C. Wainwright raises Immunic stock price target to $22 on MS drug prospects By Investing.com - Investing.com India
H.C. Wainwright raises Immunic stock price target to $22 on MS drug prospects - Investing.com UK
Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Immunic Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Immunic to present MS data, meet investors at May conferences - Proactive financial news
IMUX Forecast, Price Target & Analyst Ratings | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
Immunic, Inc. Common Stock (IMUX) Stock Price Today & Analysis - Gotrade
Debt to equity ratio of Immunic, Inc. – MUN:10V - TradingView
Total liabilities & shareholders' equities of Immunic, Inc. – MUN:10V - TradingView
Current ratio of Immunic, Inc. – MUN:10V - TradingView
Diluted earnings per share (diluted EPS) of Immunic, Inc. – MUN:10V - TradingView
Debt to equity ratio of Immunic, Inc. – LSX:A428WY - TradingView
Pretax income of Immunic, Inc. – MUN:10V - TradingView
Net income of Immunic, Inc. – MUN:10V - TradingView
Debt to equity ratio of Immunic, Inc. – LS:A428WY - TradingView
Total debt per share of Immunic, Inc. – MUN:10V - TradingView
After tax other income/expense of Immunic, Inc. – LS:A428WY - TradingView
Immunic (IMUX) awards CMO 300,000 stock options at $8.80 - Stock Titan
Immunic (IMUX) Chief Medical Officer Michael Panzara files initial Form 3 insider report - Stock Titan
Enterprise value to EBITDA ratio of Immunic, Inc. – TRADEGATE:10V - TradingView
Long term debt to total assets ratio of Immunic, Inc. – TRADEGATE:10V - TradingView
Immunic, Inc. Cash Flow – FWB:10V - TradingView
Asset turnover of Immunic, Inc. – FWB:10V - TradingView
Total liabilities & shareholders' equities of Immunic, Inc. – FWB:10V - TradingView
EBIT per share of Immunic, Inc. – GETTEX:10V - TradingView
Taxes of Immunic, Inc. – GETTEX:10V - TradingView
Current ratio of Immunic, Inc. – GETTEX:10V - TradingView
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):